SNOA

Sonoma Pharmaceuticals, Inc.

Price Chart

Latest Quote

$1.15

+0.00 (+0.00%)

Current Price

Previous Close	$1.15
Open	$1.16
Day High	$1.18
Day Low	$1.10
Volume	71,206

Fetched: 2026-06-20T00:18:42

Stock Information

Shares Outstanding	3.47M
Total Debt	$655K
Cash Equivalents	$2.56M
Revenue	$17.72M
Net Income	$-3.37M
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Market Cap	$3.99M
EPS (TTM)	$-1.89
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$-2K
Sales	$17.72M
Income	$-3.37M
Book/sh	$1.98
Cash/sh	$0.74
Employees	8

Financial Ratios

Quick Ratio	1.21
Current Ratio	2.88
Debt/Eq	19.09

Returns & Margins

ROA	-12.67%
ROE	-81.18%
Gross Margin	38.16%
Operating Margin	-15.59%
Profit Margin	-19.02%

Ownership

Insider Ownership	0.57%
Institutional Ownership	1.97%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-2.05
PEG	1.08
P/S	0.23
P/B	0.58

Analyst Data

Recommendation

none

Technical Indicators

SMA20	$1.12
SMA50	$1.37
SMA200	$2.90
RSI	51.28
ATR	0.0943

Shares Float	1.72M
Short Float	1.31%
Short Ratio	0.33
Volatility	1.30
Rel Volume	0.46

Performance History

Week	+4.55%
Month	+13.86%
Quarter	-53.06%
6 Months	-65.98%
YTD	-68.41%
Year	-61.02%
3 Years	-95.58%
5 Years	-99.28%
10 Years	-99.86%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$1.15	76,400
2026-06-17	$1.15	200,100
2026-06-16	$1.10	1,255,500
2026-06-15	$1.11	18,600
2026-06-12	$1.09	47,700
2026-06-11	$1.10	54,900
2026-06-10	$1.09	62,900
2026-06-09	$1.11	75,300
2026-06-08	$1.09	91,500
2026-06-05	$1.14	119,700
2026-06-04	$1.21	43,200
2026-06-03	$1.21	309,600
2026-06-02	$1.16	83,500
2026-06-01	$1.19	156,600
2026-05-29	$1.14	147,500
2026-05-28	$1.11	111,700
2026-05-27	$1.08	59,000
2026-05-26	$1.06	128,900
2026-05-22	$1.10	107,400
2026-05-21	$1.06	165,400
2026-05-20	$1.07	458,900
2026-05-19	$1.01	75,100

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

📰 Latest News

Despite Fast-paced Momentum, Sonoma Pharmaceuticals (SNOA) Is Still a Bargain Stock

Zacks • 2025-08-19T12:50:02Z

Sonoma Pharmaceuticals Soars 95% After Walmart, Amazon Retail Debut

GuruFocus.com • 2025-08-14T17:55:46Z

BC-Most Active Stocks

Associated Press Finance • 2025-08-14T14:30:16Z

Sonoma Pharmaceuticals (SNOA) Is Attractively Priced Despite Fast-paced Momentum

Zacks • 2025-07-14T12:50:03Z

The early winner in the 'Dexit' war for corporate relocations: Nevada

Yahoo Finance • 2025-07-10T08:00:15Z

Period:

Income Statement (Annual)

Metric	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Revenue
Reconciled Cost Of Revenue	$8,823,000	$7,990,000	$8,795,000	$8,635,000
Cost Of Revenue	$8,823,000	$7,990,000	$8,795,000	$8,635,000
Total Revenue	$14,288,000	$12,735,000	$13,272,000	$12,628,000
Operating Revenue	$14,288,000	$12,735,000	$13,272,000	$12,628,000
Expenses
Total Expenses	$17,998,000	$17,436,000	$17,842,000	$18,515,000
Other Income Expense	$803,000	$-330,000	$-614,000	$479,000
Other Non Operating Income Expenses	$803,000	$-330,000	$-614,000	$-394,000
Operating Expense	$9,175,000	$9,446,000	$9,047,000	$9,880,000
Net Non Operating Interest Income Expense	-	-	$16,000	$-10,000
Total Other Finance Cost	-	-	$-16,000	$10,000
Interest Expense	-	-	-	-
Interest Expense Non Operating	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-3,457,000	$-4,835,000	$-5,151,000	$-5,086,000
Normalized Income	$-3,457,000	$-4,835,000	$-5,151,000	$-5,904,874
Net Income From Continuing And Discontinued Operation	$-3,457,000	$-4,835,000	$-5,151,000	$-5,086,000
Total Operating Income As Reported	$-3,710,000	$-4,701,000	$-4,570,000	$-5,887,000
Net Income Common Stockholders	$-3,457,000	$-4,835,000	$-5,151,000	$-5,086,000
Net Income	$-3,457,000	$-4,835,000	$-5,151,000	$-5,086,000
Net Income Including Noncontrolling Interests	$-3,457,000	$-4,835,000	$-5,151,000	$-5,086,000
Net Income Continuous Operations	$-3,457,000	$-4,835,000	$-5,151,000	$-5,086,000
Pretax Income	$-2,907,000	$-5,031,000	$-5,184,000	$-5,418,000
Operating Income	$-3,710,000	$-4,701,000	$-4,570,000	$-5,887,000
Gross Profit	$5,465,000	$4,745,000	$4,477,000	$3,993,000
Net Interest Income	-	-	$16,000	$-10,000
Special Income Charges	-	-	$1,000	$873,000
Net Income Discontinuous Operations	-	-	-	$0
Interest Income	-	-	-	-
Interest Income Non Operating	-	-	-	-
Per Share
Diluted EPS	$-2.79	$-10.63	$-30.40	$-38.40
Basic EPS	$-2.79	$-10.63	$-30.40	$-38.40
Other
Tax Effect Of Unusual Items	$0	$0	$0	$54,126
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-3,572,000	$-4,525,000	$-4,445,000	$-6,574,000
Reconciled Depreciation	$138,000	$176,000	$125,000	$186,000
EBITDA (Bullshit earnings)	$-3,572,000	$-4,525,000	$-4,445,000	$-5,701,000
EBIT	$-3,710,000	$-4,701,000	$-4,570,000	$-5,887,000
Diluted Average Shares	$1,241,000	$455,000	$169,700	$132,650
Basic Average Shares	$1,241,000	$455,000	$169,700	$132,650
Diluted NI Availto Com Stockholders	$-3,457,000	$-4,835,000	$-5,151,000	$-5,086,000
Tax Provision	$550,000	$-196,000	$-33,000	$-332,000
Research And Development	$1,814,000	$1,871,000	$207,000	$125,000
Selling General And Administration	$7,361,000	$7,575,000	$8,840,000	$9,755,000
Total Unusual Items	-	-	$1,000	$873,000
Total Unusual Items Excluding Goodwill	-	-	$1,000	$873,000
Gain On Sale Of Ppe	-	-	$1,000	$150,000
Other Special Charges	-	-	-	$-723,000

Fetched: 2026-06-17

Balance Sheet (Annual)

Metric	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Assets
Net Tangible Assets	$4,411,000	$6,137,000	$7,977,000	$8,697,000
Total Assets	$13,693,000	$14,740,000	$16,231,000	$18,845,000
Total Non Current Assets	$1,045,000	$2,192,000	$2,433,000	$2,415,000
Other Non Current Assets	$74,000	$66,000	$73,000	$77,000
Non Current Deferred Assets	$662,000	$1,475,000	$1,454,000	$1,459,000
Non Current Deferred Taxes Assets	$589,000	$1,145,000	$949,000	$829,000
Current Assets	$12,648,000	$12,548,000	$13,798,000	$16,430,000
Other Current Assets	$148,000	$105,000	$25,000	$620,000
Current Deferred Assets	$212,000	$262,000	$240,000	$218,000
Prepaid Assets	$236,000	$340,000	$438,000	$755,000
Inventory	$2,915,000	$2,719,000	$2,858,000	$2,663,000
Receivables	$3,763,000	$5,994,000	$6,417,000	$4,778,000
Taxes Receivable	$1,531,000	$3,096,000	$3,845,000	$2,371,000
Accounts Receivable	$2,232,000	$2,898,000	$2,572,000	$2,407,000
Allowance For Doubtful Accounts Receivable	$-8,000	$-27,000	$-16,000	$-81,000
Gross Accounts Receivable	$2,240,000	$2,925,000	$2,588,000	$2,488,000
Cash Cash Equivalents And Short Term Investments	$5,374,000	$3,128,000	$3,820,000	$7,396,000
Cash And Cash Equivalents	$5,374,000	$3,128,000	$3,820,000	$7,396,000
Debt
Total Debt	$305,000	$608,000	$849,000	$1,367,000
Long Term Debt And Capital Lease Obligation	$27,000	$87,000	$162,000	$309,000
Current Debt And Capital Lease Obligation	$278,000	$521,000	$687,000	$1,058,000
Current Debt	$220,000	$323,000	$431,000	$808,000
Other Current Borrowings	-	$323,000	$431,000	$808,000
Long Term Debt	-	-	-	-
Liabilities
Total Liabilities Net Minority Interest	$9,282,000	$8,603,000	$8,254,000	$10,148,000
Total Non Current Liabilities Net Minority Interest	$5,186,000	$4,884,000	$4,537,000	$4,329,000
Tradeand Other Payables Non Current	$5,142,000	$4,710,000	$4,235,000	$3,838,000
Non Current Deferred Liabilities	$17,000	$87,000	$140,000	$182,000
Current Liabilities	$4,096,000	$3,719,000	$3,717,000	$5,819,000
Other Current Liabilities	$487,000	$694,000	$566,000	$784,000
Current Deferred Liabilities	$641,000	$478,000	$160,000	$1,277,000
Current Notes Payable	$220,000	$323,000	$431,000	-
Payables And Accrued Expenses	$2,690,000	$2,026,000	$2,304,000	$2,700,000
Payables	$953,000	$607,000	$841,000	$1,641,000
Accounts Payable	$953,000	$607,000	$841,000	$1,641,000
Liabilities Heldfor Sale Non Current	-	-	-	-
Equity
Common Stock Equity	$4,411,000	$6,137,000	$7,977,000	$8,697,000
Total Equity Gross Minority Interest	$4,411,000	$6,137,000	$7,977,000	$8,697,000
Stockholders Equity	$4,411,000	$6,137,000	$7,977,000	$8,697,000
Gains Losses Not Affecting Retained Earnings	$-4,376,000	$-2,723,000	$-3,418,000	$-4,312,000
Retained Earnings	$-197,806,000	$-194,349,000	$-189,514,000	$-184,363,000
Other
Ordinary Shares Number	$1,634,265	$780,371	$246,677	$155,046
Share Issued	$1,634,265	$780,371	$246,677	$155,046
Tangible Book Value	$4,411,000	$6,137,000	$7,977,000	$8,697,000
Invested Capital	$4,631,000	$6,460,000	$8,408,000	$9,505,000
Working Capital	$8,552,000	$8,829,000	$10,081,000	$10,611,000
Capital Lease Obligations	$85,000	$285,000	$418,000	$559,000
Total Capitalization	$4,411,000	$6,137,000	$7,977,000	$8,697,000
Additional Paid In Capital	$206,593,000	$203,209,000	$200,904,000	$197,370,000
Capital Stock	$0	$0	$5,000	$2,000
Common Stock	$0	$0	$5,000	$2,000
Preferred Stock	$0	$0	$0	$0
Non Current Deferred Revenue	$17,000	$87,000	$140,000	$182,000
Long Term Capital Lease Obligation	$27,000	$87,000	$162,000	$309,000
Current Deferred Revenue	$641,000	$478,000	$160,000	$1,277,000
Current Capital Lease Obligation	$58,000	$198,000	$256,000	$250,000
Current Accrued Expenses	$1,737,000	$1,419,000	$1,463,000	$1,059,000
Net PPE	$309,000	$651,000	$906,000	$879,000
Accumulated Depreciation	$-2,075,000	$-2,380,000	$-2,014,000	$-1,711,000
Gross PPE	$2,384,000	$3,031,000	$2,920,000	$2,590,000
Leases	$491,000	$605,000	$554,000	$503,000
Other Properties	$1,555,000	$2,062,000	$2,042,000	$1,840,000
Machinery Furniture Equipment	$338,000	$364,000	$324,000	$247,000
Properties	$0	$0	$0	$0
Inventories Adjustments Allowances	$-298,000	$-296,000	$-236,000	-
Finished Goods	$1,818,000	$1,213,000	$1,330,000	$1,037,000
Raw Materials	$1,395,000	$1,802,000	$1,764,000	$1,626,000

Fetched: 2026-06-17

Cash Flow Statement (Annual)

Metric	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Free Cash Flow
Free Cash Flow	$-168,000	$-2,400,000	$-6,421,000	$-4,385,000
Operating Activities
Operating Cash Flow	$-88,000	$-2,398,000	$-6,152,000	$-4,248,000
Cash Flow From Continuing Operating Activities	$-88,000	$-2,398,000	$-6,152,000	$-4,248,000
Operating Gains Losses	-	-	$-1,000	$-723,000
Investing Activities
Capital Expenditure	$-80,000	$-2,000	$-269,000	$-137,000
Investing Cash Flow	$-80,000	$-2,000	$-258,000	$-99,000
Cash Flow From Continuing Investing Activities	$-80,000	$-2,000	$-258,000	$-99,000
Net Other Investing Changes	-	$15,000	$11,000	$38,000
Financing Activities
Repurchase Of Capital Stock	$-1,000	$0	-	-
Issuance Of Capital Stock	$3,079,000	$1,784,000	$2,868,000	$7,554,000
Financing Cash Flow	$3,030,000	$1,676,000	$2,489,000	$7,396,000
Cash Flow From Continuing Financing Activities	$3,030,000	$1,676,000	$2,489,000	$7,396,000
Net Other Financing Charges	$274,000	$373,000	$515,000	-
Net Common Stock Issuance	$3,078,000	$1,784,000	$2,868,000	$7,554,000
Common Stock Issuance	$3,079,000	$1,784,000	$2,868,000	$7,554,000
Other
Repayment Of Debt	$-404,000	$-481,000	$-894,000	$-497,000
Interest Paid Supplemental Data	$11,000	$22,000	$17,000	$24,000
End Cash Position	$5,374,000	$3,128,000	$3,820,000	$7,396,000
Beginning Cash Position	$3,128,000	$3,820,000	$7,396,000	$4,220,000
Effect Of Exchange Rate Changes	$-616,000	$32,000	$345,000	$127,000
Changes In Cash	$2,862,000	$-724,000	$-3,921,000	$3,049,000
Proceeds From Stock Option Exercised	$82,000	$0	$0	$216,000
Common Stock Payments	$-1,000	$0	-	-
Net Issuance Payments Of Debt	$-404,000	$-481,000	$-894,000	$-374,000
Net Short Term Debt Issuance	$-404,000	$-481,000	$-774,000	$-374,000
Short Term Debt Payments	$-404,000	$-481,000	$-774,000	$-497,000
Net PPE Purchase And Sale	$-80,000	$-2,000	$-269,000	$-137,000
Purchase Of PPE	$-80,000	$-2,000	$-269,000	$-137,000
Change In Working Capital	$2,476,000	$1,693,000	$-1,930,000	$3,131,000
Change In Other Working Capital	$375,000	$577,000	$-1,106,000	$1,060,000
Change In Other Current Liabilities	$-174,000	$-161,000	$-173,000	$-222,000
Change In Payables And Accrued Expense	$1,143,000	$216,000	$-341,000	$882,000
Change In Accrued Expense	$295,000	$19,000	$127,000	$679,000
Change In Payable	$848,000	$197,000	$-468,000	$203,000
Change In Account Payable	$416,000	$-278,000	$-864,000	$-157,000
Change In Tax Payable	$432,000	$475,000	$396,000	$360,000
Change In Income Tax Payable	$432,000	$475,000	$396,000	$360,000
Change In Prepaid Assets	$1,086,000	$1,107,000	$-306,000	$-460,000
Change In Inventory	$-388,000	$184,000	$0	$-100,000
Change In Receivables	$434,000	$-230,000	$-4,000	$1,971,000
Changes In Account Receivables	$434,000	$-230,000	$-4,000	$1,971,000
Other Non Cash Items	$174,000	$161,000	$173,000	$223,000
Stock Based Compensation	$224,000	$516,000	$669,000	$382,000
Deferred Tax	$357,000	$-109,000	$-37,000	$-829,000
Deferred Income Tax	$357,000	$-109,000	$-37,000	$-829,000
Depreciation Amortization Depletion	$138,000	$176,000	$125,000	$186,000
Depreciation And Amortization	$138,000	$176,000	$125,000	$186,000
Depreciation	$138,000	$176,000	$125,000	$186,000
Net Income From Continuing Operations	$-3,457,000	$-4,835,000	$-5,151,000	$-5,086,000
Net Long Term Debt Issuance	-	$0	$-120,000	$-467,000
Long Term Debt Payments	-	$0	$-120,000	$-467,000
Issuance Of Debt	-	-	$515,000	$123,000
Income Tax Paid Supplemental Data	-	-	$0	$767,000
Short Term Debt Issuance	-	-	$515,000	$123,000
Provisionand Write Offof Assets	-	-	$-66,000	$-1,532,000
Long Term Debt Issuance	-	-	-	$0
Net Intangibles Purchase And Sale	-	-	-	$0
Sale Of Intangibles	-	-	-	$0
Net Business Purchase And Sale	-	-	-	-
Sale Of Business	-	-	-	-
Gain Loss On Sale Of PPE	-	-	-	-

Fetched: 2026-06-17